Pharmaceuticals - Iraq

  • Iraq
  • The Pharmaceuticals market in Iraq is expected to witness significant revenue growth in the coming years.
  • By 2024, the projected revenue is estimated to reach US$1,252.00m.
  • The market's largest segment, Oncology Drugs, is anticipated to contribute significantly to this growth, with a projected market volume of US$216.70m in 2024.
  • Furthermore, the Pharmaceuticals market is expected to demonstrate a steady annual growth rate of 5.13% from 2024 to 2029.
  • This growth trajectory is projected to result in a market volume of US$1,608.00m by 2029.
  • In terms of global comparison, United States is forecasted to generate the highest revenue in the Pharmaceuticals market.
  • In 2024 alone, United States is projected to generate an impressive US$630.30bn in revenue.
  • This showcases the dominance of the United States in the global Pharmaceuticals market.
  • Iraq's pharmaceutical market is experiencing a surge in demand for essential medicines due to the country's growing population and increased healthcare awareness.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The pharmaceuticals market in Iraq has experienced significant growth in recent years, driven by a number of factors.

Customer preferences:
Iraqi consumers have become increasingly health-conscious in recent years, leading to a growing demand for pharmaceutical products. Additionally, the country's aging population has contributed to the rising demand for healthcare services and medication.

Trends in the market:
One of the key trends in the Iraqi pharmaceuticals market is the increasing availability of generic drugs. This has been driven by government efforts to reduce healthcare costs and improve access to affordable medication. As a result, many multinational pharmaceutical companies have started to focus on developing generic versions of their drugs for the Iraqi market.Another trend in the market is the growing importance of local pharmaceutical manufacturers. These companies have benefited from government support and incentives, as well as a growing demand for locally-produced medication. This has led to increased competition in the market, as well as a greater emphasis on quality and innovation.

Local special circumstances:
The pharmaceuticals market in Iraq is heavily regulated, with strict rules governing the import, manufacture, and sale of medication. This has created significant barriers to entry for foreign companies, and has also led to a shortage of certain types of medication in the country.In addition, the ongoing conflict in Iraq has had a significant impact on the pharmaceuticals market. Many healthcare facilities have been damaged or destroyed, and access to medication and other essential healthcare services has been severely limited in some areas.

Underlying macroeconomic factors:
The Iraqi pharmaceuticals market is heavily influenced by a number of macroeconomic factors, including government policies, healthcare spending, and the overall economic climate. The government's focus on reducing healthcare costs and improving access to medication has been a major driver of growth in the market, as has the country's growing population and increasing healthcare needs.At the same time, the ongoing conflict in Iraq has had a negative impact on the pharmaceuticals market, particularly in areas that have been heavily affected by the conflict. The overall economic climate in the country has also been challenging in recent years, with low oil prices and political instability contributing to a difficult business environment for many companies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)